Quarterly report [Sections 13 or 15(d)]

Commitments and Contingencies (Details)

v3.25.1
Commitments and Contingencies (Details)
3 Months Ended
Jul. 19, 2022
USD ($)
Mar. 31, 2025
USD ($)
Mar. 31, 2024
USD ($)
Mar. 31, 2023
Site
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
General and administration   $ 4,092,000 $ 7,299,000  
Linebacker License Agreements        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Upfront license fee $ 50,000      
License agreement term (in days) 10 days      
License or royalty net revenue percentage 3.00%      
Royalty expense $ 250,000      
General and administration   0 100,000  
Linebacker License Agreements | Phase 3        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Additional payment of fee 900,000      
Linebacker License Agreements | New Drug Application        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
Additional payment of fee $ 1,000,000      
Equivir License Agreement        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
General and administration   0 100,000  
Number of sites | Site       8
BE-Smart License Agreement        
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]        
General and administration   $ 0 $ 200,000